Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTISITE vs ARESTIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-t RNA from binding to the A site.
Minocycline is a semisynthetic tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the elongating peptide chain. This action is bacteriostatic. In periodontal disease, it also inhibits matrix metalloproteinases (MMPs), particularly collagenase, and suppresses inflammatory cytokine production, reducing tissue destruction.
Treatment of periodontal disease (adjunct to scaling and root planing),Topical treatment of infected wounds and skin ulcers
Adjunctive treatment of periodontitis (subgingival administration by a dental professional),Off-label: Treatment of acne vulgaris, rosacea, rheumatoid arthritis (MRSA decolonization is not standard)
Topical application of tetracycline hydrochloride 10 mg/g periodontal fiber. Inserted into periodontal pocket and left in place for 10 days.
1 mg subgingival application per periodontal pocket, applied as a single dose by a dental professional.
Not applicable due to local degradation; systemic half-life is negligible as tetracycline hydrochloride is not absorbed.
The terminal elimination half-life of minocycline is 11-17 hours (mean ~16 hours). This long half-life allows for twice-daily dosing in systemic use, but for Arestin (subgingival), local sustained release provides prolonged local exposure.
Not significantly metabolized; primarily excreted unchanged in urine and feces.
Minocycline is extensively metabolized in the liver via multiple pathways, with at least 6 metabolites identified. The major metabolic routes include hydroxylation at the 9-position (via CYP450 enzymes, possibly CYP3A4) and N-demethylation. It also undergoes glucuronidation. The drug has a long half-life (11–17 hours) and undergoes enterohepatic recirculation.
Primarily eliminated by phagocytic degradation at the application site; minimal systemic absorption, negligible renal or biliary excretion.
Minocycline is primarily eliminated via hepatic metabolism and biliary/fecal excretion. Renal excretion accounts for approximately 10-20% of the dose, with the remainder excreted in feces via bile. Less than 10% is recovered unchanged in urine.
Not applicable (no systemic absorption); if systemically present, tetracycline is 50-60% bound to plasma proteins.
Minocycline is approximately 70-75% bound to plasma proteins.
Not applicable due to lack of systemic absorption; if systemic, tetracycline Vd is 1.3-1.6 L/kg.
Volume of distribution for minocycline is 1.0-1.3 L/kg, indicating extensive tissue penetration, consistent with its lipophilic nature and ability to concentrate in various tissues including gingival crevicular fluid.
Negligible systemic bioavailability (<0.1%) when applied topically; not administered orally or intravenously for periodontal use.
Subgingival administration: Direct local delivery results in negligible systemic absorption (bioavailability <1% relative to oral dose). Oral minocycline bioavailability is approximately 90-100%.
Not systemically absorbed; no renal adjustment required.
No dose adjustment required for renal impairment.
Not systemically absorbed; no hepatic adjustment required.
No dose adjustment required for hepatic impairment.
Safety and efficacy not established in pediatric patients.
Not recommended in pediatric patients below 18 years of age due to lack of safety and efficacy data.
No specific dose adjustment; use standard adult dosing with caution for age-related comorbidities.
No specific dose adjustment; use with caution due to potential age-related comorbidities.
None
None.
Photosensitivity,Superinfection with resistant organisms,Use in renal impairment may require dose adjustment,Not recommended in children under 8 years due to permanent tooth discoloration
Photosensitivity: May cause exaggerated sunburn; avoid prolonged sun exposure.,Superinfection: Use may result in overgrowth of nonsusceptible organisms, including fungi.,Hepatotoxicity: Rare cases of liver injury; discontinue if symptoms occur.,Renal impairment: Use with caution in renal dysfunction; may accumulate.,Autoimmune syndromes: Cases of drug-induced lupus, serum sickness-like reactions, and vasculitis reported.,Intracranial hypertension: Associated with minocycline; symptoms include headache and blurred vision.,Tooth discoloration: May cause permanent discoloration of teeth in children under 8 years.,Bone development: Use during pregnancy may affect fetal skeletal development.
Hypersensitivity to tetracyclines,Severe renal impairment
Hypersensitivity to any tetracycline antibiotic.,Pregnancy (especially second and third trimesters) – risk of fetal harm.,Lactation – excreted in breast milk, potential for adverse effects in nursing infants.,Children under 8 years of age – risk of permanent tooth discoloration.
No direct food interactions. Avoid eating on the treated side to prevent dislodgement of the fiber. Maintain soft diet to minimize trauma. Avoid alcohol-based mouthwashes.
No known food interactions. Patients should avoid hard, crunchy, or sticky foods for at least 7 days after application to prevent mechanical disruption of the microspheres.
FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, tetracycline hydrochloride (active component) caused fetal toxicity (skeletal malformations, reduced fetal weight) at doses 1-2 times the human dose. First trimester: potential for teratogenicity (neural tube defects, cardiovascular anomalies). Second and third trimesters: risk of permanent tooth discoloration (yellow-gray-brown) and enamel hypoplasia in the fetus; also potential for inhibition of fetal bone growth and maternal hepatotoxicity. Use only if potential benefit outweighs risk.
ARESTIN (minocycline hydrochloride) is a tetracycline antibiotic. Class D: Positive evidence of human fetal risk. Use contraindicated in pregnancy. Risk is highest in second and third trimesters due to tetracycline deposition in fetal bones and teeth, causing permanent discoloration and enamel hypoplasia. Potential for reversible inhibition of bone growth. First trimester exposure may be associated with neural tube defects and cardiac malformations, though data are limited.
Tetracycline is excreted in human milk (M/P ratio approximately 0.6-1.5). Due to potential for serious adverse reactions (tooth discoloration, bone growth inhibition, photosensitivity) in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Avoid prolonged use during breastfeeding.
Minocycline is excreted into human breast milk with an M/P ratio of approximately 0.6 to 0.8. Theoretical risk of permanent tooth discoloration and bone growth inhibition in nursing infants. Avoid use in breastfeeding women; if necessary, consider temporary cessation of breastfeeding. Alternative antibiotics are preferred.
No specific dose adjustments for ACTISITE (tetracycline periodontal fiber). Systemic absorption minimal (peak serum concentrations <0.1 mcg/m L). Pregnancy may alter pharmacokinetics of tetracycline (increased volume of distribution, decreased protein binding), but due to local administration, systemic effects are negligible. No dosage adjustment required for the fiber formulation; however, avoid systemic tetracycline use during pregnancy when possible.
Pregnancy is a contraindication; ARESTIN should not be used. Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced clearance) may reduce minocycline levels, but no dose adjustments are recommended because the drug is contraindicated. No studies establish safe dosing in pregnancy.
ACTISITE (tetracycline hydrochloride) periodontal fiber is a controlled-release local antibiotic for adjunctive treatment of chronic periodontitis. Insert fiber into periodontal pocket to deliver drug over 10 days. Ensure pocket depth is ≥5mm. Do not use with metallic or synthetic fibers. Fiber must be secured with cyanoacrylate adhesive. Monitor for foreign body sensation, pain, or infection. Removal at 10 days is mandatory to avoid excessive tissue reaction. Not for acute abscesses.
ARESTIN (minocycline microspheres) is a locally administered antibiotic adjunct to scaling and root planing (SRP) for periodontitis. Do not use in patients with known hypersensitivity to tetracyclines. Avoid placement in areas with active abscesses. Apply only into periodontal pockets ≥5 mm. Do not pack deeply; overfill may cause tissue irritation. No systemic antibiotic effect; monitor for local adverse effects like pain or swelling.
Do not brush or floss the treated area while the fiber is in place.,Avoid chewing hard or sticky foods on the treated side.,You may feel a mild foreign body sensation; report severe pain or swelling.,The fiber must be removed after 10 days; do not leave it longer.,Complete the full course of prescribed oral hygiene and antibiotics if given.
Do not brush, floss, or use interdental cleaners in the treated area for 7 days after application.,Avoid eating hard, crunchy, or sticky foods for 1 week to prevent dislodging the microspheres.,Some minor discomfort, redness, or swelling at the application site is normal and usually resolves within days.,Report severe pain, swelling, or signs of infection (e.g., pus, fever) to your dentist promptly.,Continue routine oral hygiene in untreated areas as directed by your dentist.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTISITE vs ARESTIN, answered by our medical review team.
ACTISITE is a Tetracycline Antibiotic that works by Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-t RNA from binding to the A site.. ARESTIN is a Tetracycline Antibiotic that works by Minocycline is a semisynthetic tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the elongating peptide chain. This action is bacteriostatic. In periodontal disease, it also inhibits matrix metalloproteinases (MMPs), particularly collagenase, and suppresses inflammatory cytokine production, reducing tissue destruction.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTISITE and ARESTIN depend on the specific clinical indication. These are both Tetracycline Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTISITE is: Topical application of tetracycline hydrochloride 10 mg/g periodontal fiber. Inserted into periodontal pocket and left in place for 10 days.. The standard adult dose of ARESTIN is: 1 mg subgingival application per periodontal pocket, applied as a single dose by a dental professional.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTISITE and ARESTIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTISITE is classified as Category C. FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, tetracycline hydrochloride (active component) caused fetal toxicity (skeletal malformations, red. ARESTIN is classified as Category C. ARESTIN (minocycline hydrochloride) is a tetracycline antibiotic. Class D: Positive evidence of human fetal risk. Use contraindicated in pregnancy. Risk is highest in second and th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.